X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PANACEA BIOTECH ELDER PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x -0.2 155.4 - View Chart
P/BV x 0.1 3.5 2.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PANACEA BIOTECH
Mar-14
ELDER PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs380149 255.5%   
Low Rs18882 228.4%   
Sales per share (Unadj.) Rs491.284.1 583.8%  
Earnings per share (Unadj.) Rs-3.2-18.3 17.4%  
Cash flow per share (Unadj.) Rs14.4-6.7 -215.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.583.7 449.8%  
Shares outstanding (eoy) m20.5461.25 33.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.4 42.1%   
Avg P/E ratio x-89.3-6.3 1,414.8%  
P/CF ratio (eoy) x19.7-17.2 -114.3%  
Price / Book Value ratio x0.81.4 54.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,8337,074 82.5%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,1791,449 150.4%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m10,0895,154 195.8%  
Other income Rs m257100 257.1%   
Total revenues Rs m10,3465,254 196.9%   
Gross profit Rs m-792-766 103.3%  
Depreciation Rs m361711 50.8%   
Interest Rs m2,7561,503 183.4%   
Profit before tax Rs m-3,653-2,881 126.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m3,7131,771 209.7%   
Tax Rs m12517 744.9%   
Profit after tax Rs m-65-1,121 5.8%  
Gross profit margin %-7.8-14.9 52.8%  
Effective tax rate %-3.4-0.6 587.4%   
Net profit margin %-0.6-21.8 3.0%  
BALANCE SHEET DATA
Current assets Rs m9,2403,810 242.5%   
Current liabilities Rs m9,9988,365 119.5%   
Net working cap to sales %-7.5-88.4 8.5%  
Current ratio x0.90.5 202.9%  
Inventory Days Days46156 29.7%  
Debtors Days Days6067 89.2%  
Net fixed assets Rs m10,12414,480 69.9%   
Share capital Rs m20661 335.6%   
"Free" reserves Rs m5,582903 618.1%   
Net worth Rs m7,7345,127 150.8%   
Long term debt Rs m4,8895,832 83.8%   
Total assets Rs m22,88219,433 117.7%  
Interest coverage x-0.3-0.9 35.5%   
Debt to equity ratio x0.61.1 55.6%  
Sales to assets ratio x0.40.3 166.3%   
Return on assets %11.82.0 598.7%  
Return on equity %-0.8-21.9 3.9%  
Return on capital %22.33.6 613.5%  
Exports to sales %3.024.5 12.4%   
Imports to sales %0.410.2 4.2%   
Exports (fob) Rs m3071,264 24.3%   
Imports (cif) Rs m43525 8.2%   
Fx inflow Rs m3071,539 19.9%   
Fx outflow Rs m125942 13.3%   
Net fx Rs m181597 30.4%   
CASH FLOW
From Operations Rs m11,754599 1,961.6%  
From Investments Rs m-561-438 128.0%  
From Financial Activity Rs m-6,762-303 2,234.6%  
Net Cashflow Rs m4,432-141 -3,136.4%  

Share Holding

Indian Promoters % 39.6 74.5 53.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 0.6 1,250.0%  
FIIs % 16.8 1.3 1,292.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 23.6 153.0%  
Shareholders   16,479 10,259 160.6%  
Pledged promoter(s) holding % 77.6 35.1 221.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Consumer Durables Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed buying activity throughout the day and ended the day on a positive note.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Investing Process With the Best Possible Returns(The 5 Minute Wrapup)

Nov 16, 2017

Buffett did not become a billionaire following the herd but by following his process.

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

ICICI Prudential Mutual Fund Bharat 22 ETF: Important Facts You Must Know(Outside View)

Nov 16, 2017

All you need to know about the ICICI Prudential Mutual Fund Bharat 22 ETF.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - DR. DATSONS LABS COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS